D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Genetics D-index 62 Citations 11,041 231 World Ranking 2196 National Ranking 985

Overview

What is she best known for?

The fields of study she is best known for:

  • Gene
  • Mutation
  • Genetics

Ludwine Messiaen mainly investigates Genetics, Mutation, Exon, Neurofibromatosis and Gene. Ludwine Messiaen regularly links together related areas like Molecular biology in her Genetics studies. Her study in Molecular biology is interdisciplinary in nature, drawing from both Multiplex ligation-dependent probe amplification, Frameshift mutation and Breakpoint.

Her work deals with themes such as Carcinogenesis, Forkhead box L2, Blepharophimosis and Neurofibroma, which intersect with Mutation. Her Exon study incorporates themes from Open reading frame, Polymerase chain reaction and Mutation. Her research investigates the connection with Neurofibromatosis and areas like Legius syndrome which intersect with concerns in Phenotype.

Her most cited work include:

  • Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. (373 citations)
  • Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. (327 citations)
  • An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in Exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation (244 citations)

What are the main themes of her work throughout her whole career to date?

Genetics, Neurofibromatosis, Gene, Pathology and Molecular biology are her primary areas of study. Her study in Mutation, Exon, Breakpoint, Missense mutation and Germline mutation is carried out as part of her studies in Genetics. Her Mutation research is multidisciplinary, incorporating perspectives in Neurofibromin 1 and Somatic cell.

Her Germline mutation study combines topics from a wide range of disciplines, such as Germline and Loss of heterozygosity. As a part of the same scientific family, Ludwine Messiaen mostly works in the field of Neurofibromatosis, focusing on Legius syndrome and, on occasion, Macrocephaly. Her specific area of interest is Gene, where Ludwine Messiaen studies Mutation testing.

She most often published in these fields:

  • Genetics (53.26%)
  • Neurofibromatosis (25.29%)
  • Gene (20.31%)

What were the highlights of her more recent work (between 2014-2021)?

  • Neurofibromatosis (25.29%)
  • Genetics (53.26%)
  • Legius syndrome (10.34%)

In recent papers she was focusing on the following fields of study:

Her primary scientific interests are in Neurofibromatosis, Genetics, Legius syndrome, Gene and Missense mutation. Her Neurofibromatosis research is multidisciplinary, relying on both Germline mutation, Pediatrics and Internal medicine. In general Genetics study, her work on Mutation, Copy-number variation and Neurofibromin 1 often relates to the realm of PRDM9 and Non-allelic homologous recombination, thereby connecting several areas of interest.

Her Legius syndrome research includes elements of Differential diagnosis, Dermatology and Noonan syndrome. In the subject of general Gene, her work in Genotype phenotype, Clinical phenotype and Allele is often linked to Correlation and Frame, thereby combining diverse domains of study. Her Missense mutation research integrates issues from EVH1 domain, Proband, Pulmonic stenosis, Spinal neurofibromas and Neurofibromatosis type I.

Between 2014 and 2021, her most popular works were:

  • High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. (85 citations)
  • Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848 (65 citations)
  • Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination (59 citations)

In her most recent research, the most cited papers focused on:

  • Gene
  • Mutation
  • DNA

Her primary areas of study are Genetics, Neurofibromatosis, Missense mutation, Mutation and Neurofibromin 1. The study incorporates disciplines such as Germline mutation, Legius syndrome and Internal medicine, Noonan syndrome in addition to Neurofibromatosis. Her research in Noonan syndrome intersects with topics in Clinical phenotype, Gene and Neurofibroma.

Her biological study spans a wide range of topics, including Genetic disorder, Proband, Pulmonic stenosis, Spinal neurofibromas and Neurofibromatosis type I. Her Mutation research incorporates themes from Transcriptional regulation, HEK 293 cells, Haploinsufficiency, Cullin and Cell biology. The various areas that Ludwine Messiaen examines in her Neurofibromin 1 study include Cancer research, Genetically engineered, Disease, Loss of heterozygosity and Kinase.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.

Ludwine M. Messiaen;Tom Callens;Geert Mortier;Diane Beysen.
Human Mutation (2000)

585 Citations

Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.

Hilde Brems;Magdalena Chmara;Magdalena Chmara;Mourad Sahbatou;Ellen Denayer.
Nature Genetics (2007)

483 Citations

An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in Exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation

M. Upadhyaya;S. M. Huson;M. Davies;N. Thomas.
American Journal of Human Genetics (2007)

412 Citations

Evolution and expression of FOXL2

J Cocquet;E Pailhoux;F Jaubert;N Servel.
Journal of Medical Genetics (2002)

312 Citations

Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype–phenotype correlation

Elfride De Baere;Michael J. Dixon;Kent W. Small;Ethylin W. Jabs.
Human Molecular Genetics (2001)

310 Citations

FOXL2 and BPES: Mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation

Elfride De Baere;Diane Beysen;Christine Oley;Birgit Lorenz.
American Journal of Human Genetics (2003)

282 Citations

Elucidating distinct roles for NF1 in melanomagenesis.

Ophélia Maertens;Bryan Johnson;Bryan Johnson;Pablo Hollstein;Pablo Hollstein;Dennie T. Frederick.
Cancer Discovery (2013)

255 Citations

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients

Ophélia Maertens;Hans Prenen;Maria Debiec-Rychter;Agnieszka Wozniak.
Human Molecular Genetics (2006)

247 Citations

Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas

Arkadiusz Piotrowski;Arkadiusz Piotrowski;Jing Xie;Ying F Liu;Andrzej B Poplawski.
Nature Genetics (2014)

229 Citations

Mutations of VMD2 Splicing Regulators Cause Nanophthalmos and Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC)

Jill Yardley;Bart P Leroy;Niki Hart-Holden;Bart A Lafaut.
Investigative Ophthalmology & Visual Science (2004)

221 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ludwine Messiaen

Reiner A. Veitia

Reiner A. Veitia

Université Paris Cité

Publications: 55

David H. Gutmann

David H. Gutmann

Washington University in St. Louis

Publications: 48

Meena Upadhyaya

Meena Upadhyaya

Cardiff University

Publications: 46

David Neil Cooper

David Neil Cooper

Cardiff University

Publications: 44

Hildegard Kehrer-Sawatzki

Hildegard Kehrer-Sawatzki

University of Ulm

Publications: 39

Conxi Lázaro

Conxi Lázaro

Instituto de Salud Carlos III

Publications: 37

Nancy Ratner

Nancy Ratner

Cincinnati Children's Hospital Medical Center

Publications: 33

Eric Legius

Eric Legius

KU Leuven

Publications: 32

David H. Viskochil

David H. Viskochil

University of Utah

Publications: 32

Bruce R. Korf

Bruce R. Korf

University of Alabama at Birmingham

Publications: 29

D. Gareth Evans

D. Gareth Evans

University of Manchester

Publications: 28

Marc Fellous

Marc Fellous

Bayer Pharmaceuticals

Publications: 28

Jan P. Dumanski

Jan P. Dumanski

Uppsala University

Publications: 22

Kathleen Claes

Kathleen Claes

Ghent University Hospital

Publications: 22

Amanda B. Spurdle

Amanda B. Spurdle

QIMR Berghofer Medical Research Institute

Publications: 21

Pierre Wolkenstein

Pierre Wolkenstein

Assistance Publique – Hôpitaux de Paris

Publications: 20

Trending Scientists

Jeffrey L. Callen

Jeffrey L. Callen

University of Toronto

Eric T. Chung

Eric T. Chung

Chinese University of Hong Kong

Ji-Feng Zhang

Ji-Feng Zhang

Chinese Academy of Sciences

Aleš Štrancar

Aleš Štrancar

BIA Separations (Slovenia)

Jyoti Chattopadhyaya

Jyoti Chattopadhyaya

Uppsala University

Hamidreza Arandiyan

Hamidreza Arandiyan

University of Sydney

Patricia Rousselle

Patricia Rousselle

Institut de Biologie et de Chimie des Protéines

Shivendra V. Singh

Shivendra V. Singh

University of Pittsburgh

Hongyan Liu

Hongyan Liu

Peking University

Nam-Chul Ha

Nam-Chul Ha

Seoul National University

Ethan Rubinstein

Ethan Rubinstein

University of Manitoba

John W. McCauley

John W. McCauley

The Francis Crick Institute

Scott E. Hemby

Scott E. Hemby

High Point University

Martine Hoogman

Martine Hoogman

Radboud University Nijmegen

Michael C. Crair

Michael C. Crair

Yale University

John W. Greiner

John W. Greiner

National Institutes of Health

Something went wrong. Please try again later.